Skip to content
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
Menu
Technology
Pipeline
News
Press
People
Partners
Careers
Contact
Endogena Therapeutics holds investor call and gives update on Retinitis Pigmentosa Clinical Trial
Zürich, Switzerland, February 7, 2024
Listen to a testimonial from one of our principal investigators Dr. Victor Gonzalez.
Prev
Previous
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment